Rupsa Boelig, MD
Rupsa C. Boelig, MD,
Assistant Professor, Director of the Department of Obstetrics and Gynecology Medical Research Unit,
Sidney Kimmel Medical College, Thomas Jefferson University
Biography
Dr. Rupsa Boelig is a Maternal Fetal Medicine specialist and clinical researcher. She's an Assistant Professor and the Director of the Department of Obstetrics and Gynecology Medical Research Unit at Thomas Jefferson University Center City campus. Her research has focused on the prediction and prevention of preterm and preeclamspia, which are pregnancy complications that she has battled personally and professionally. She's specifically interested in how therapies can be better targeted to provide the most benefit for each individual. She applies principals of clinical pharmacology to pregnancy specific research to improve our understanding and treatment of pregnancy related conditions. In addition to preeclampsia and preterm birth, Dr. Boelig’s research includes optimizing therapies for opioid use disorder, iron deficiency, and COVID-19 in pregnancy. Her research is funded by NICHD, EW Thrasher Foundation, March of Dimes, Pharmacosmos, and Covis Pharma.
Education
BA, Biochemistry and Cell Biology, Rice University (2007)
MD, Medical Doctor, Johns Hopkins School of Medicine (2011)
MS, Clinical Pharmacology/Human Investigation, Thomas Jefferson University (2019)
Residency, Obstetrics and Gynecology, Thomas Jefferson University (2015)
Fellowship, Maternal Fetal Medicine, Thomas Jefferson University (2019)
Fellowship, T32 Clinical Pharmacology, Thomas Jefferson University (2019)
Honors and recognition
March of Dimes Community Development Award (2018)
AMAG Research Award in Preeclampsia and Preterm Birth (2019)
March of Dimes Novel Discovery Grant (2020)
PhRMA Foundation Faculty Development Award (2020)
Selected publications
- Boelig RC, Cahanap TJ, Ma L, Zhan T, Berghella V, Chan JSY, Kraft WK, McKenzie SE . “Platelet protease activated receptor 4 (PAR 4) Receptor Genotype is Associated with an Increased Risk of Preterm Birth.” Journal of Thrombosis and Haemostasis. Online. Jul 11, 2022.
- Boelig RC, Aghai Z, Chaudhury S, et al. “Impact of COVID-19 disease and vaccination on maternal/fetal inflammatory response, placental pathology, and perinatal outcomes.” Am J Obstet Gynecol. 2022
- Boelig RC, Schoen C, Frey H et al. “Vaginal progesterone versus Intramuscular 17-hydroxyprogesterone caproate for Prevention of recurrent preterm birth (VIP): a randomized controlled trial. American Journal of Obstetrics and Gynecology. Online Feb 18 2022.
- Boelig RC, McIntosh J, Feltovich H, House M. “Cervical Length Ultrasound for Evaluation of Preterm Labor: A survey of national use and review of evidence.” American Journal of Perinatology. Online 2022.
- Boelig RC, Aagaard KM, Debbink MP et al. “Society for Maternal-Fetal Medicine Special Statement: COVID-19 research in pregnancy: progress and potential.” American Journal of Obstetrics and Gynecology. 2021 Dec. 225(6):B19-31.
- Boelig RC, Kripalu V, Chen SL, Cruz Y, Roman A, Berghella V. “Utility of Follow up Cervical Length Screening in Low Risk Women with Cervical Length 26-29mm. Am J Obstet Gynecol. 2021 Aug 225(2).
- Boelig RC, Lam E, Rochani A, Kaushal G et al. “Longitudinal evaluation of azithromycin and cytokine concentrations in amniotic fluid following one-time oral dosing in pregnancy.” Clin Transl Sci. 2021 Nov. 14(6):2431-2439.
- Boelig RC, Wanees M, Zhan T, Berghella V, Roman A. “Improving utilization of aspirin for prevention of preeclampsia in a high risk urban cohort: a prospective cohort study.” Am J Perinatol. 2020.
- Boelig RC, Naert MN, Fox NS, Hennessy S, Chervoneva I, Berghella V, Roman A. “Predictors of Early Preterm Birth Despite Vaginal Progesterone Therapy in Singletons with Short Cervix.” Am J Perinatol. 2020 Apr 28.
- Boelig RC, Zuppa A, Kraft WK, Caritis S. “Pharmacokinetics of vaginal progesterone in pregnancy” American Journal of Obstetrics and Gynecology. 2019.